CLINICAL_TRIALS
trial_result
· 2022-02-10
Clinical Trial Update: Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer [Phase 2]
Summary
Phase 2 clinical trial update for Poziotinib in HER2-positive metastatic breast cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-10